
ARE Stock Forecast & Price Target
ARE Analyst Ratings
Bulls say
Alexandria Real Estate Equities Inc. is positioned favorably due to a significant $10.8 billion backlog in construction projects and an anticipated recovery in demand for life science and technology spaces, driven by ongoing public sector investments and private sector expansions. The company’s strategic focus on life science real estate equips it to capitalize on the growing need for purpose-built facilities, particularly as biotech valuations recover and open avenues for IPOs that increase capital demand. Additionally, a potential uptick in technology growth, especially in AI, is likely to absorb newly developed lab spaces, providing further support for sustained tenant growth and occupancy rates.
Bears say
The analysis highlights a significant negative outlook for Alexandria Real Estate Equities Inc, driven primarily by declining operating results and occupancy rates exacerbated by a projected oversupply of life science office space. Year-over-year performance deterioration reflects not only a slowdown in capital formation within the life science sector but also increased challenges from slowed lease-ups of new developments and delays in asset sales. Further compounding these issues are legislative constraints impacting research funding and a potential government shutdown, which collectively threaten the company’s revenue and earnings growth prospects into 2026.
This aggregate rating is based on analysts' research of Alexandria Real Estate Equities and is not a guaranteed prediction by Public.com or investment advice.
ARE Analyst Forecast & Price Prediction
Start investing in ARE
Order type
Buy in
Order amount
Est. shares
0 shares